Ann: Imugene to Present at Annual JPMorgan Healthcare Conference, page-64

Hey GMT2

It's an interesting slide. No new results - this is still the 31 Oct 2023 data cut (though the slide has a typo and says 31 Oct 2024). However it does give more detail than we have seen previously.

The thing that jumps out at me is this:

Every patient who showed as "Progressive Disease" at their Day 42 scan is marked as "Off Treatment." Also one of the Stable Disease patients at Day 42. I interpret this as (understandably) - that they have chosen to pursue another line of therapy, which immediately took them off the MAST trial.

This is understandable - they were unwell and seemed to be getting worse ("Progressive Disease") - but because they have left the study we will never know if they later improved (ie if they were just showing Pseudo-progression). This reminds me of the interesting case of the woman on the Checkvacc trial, who left the trial early because her breast cancer lesions grew larger - but then achieved an enormous reduction in her cancer lesions. However - because by then she had started on another treatment, the cause of the reduction could not be proven as Checkvacc.

8 of the Stable Disease patients and one of the Partial response patients have gone "Off Treatment" at a later point - up to and just after 100 days. As well - two of the patients went "Off Treatment" before their day 42 scan - so they will never have a scan to show whether they were PD, PR or CR.

It is possible that some of those patients died. I suspect most simply opted to go to another treatment - and that choice exited them from the MAST study. (You can't be included in the trial if you are receiving a different treatment). Again - this is an understandable choice. If you achieve "Stable Disease" you then want to do even better - but the MAST trial protocol does not allow them to go to a higher dose of Vaxinia, so they have chosen to try the next possible treatment option.

It seems likely that most of the Progressive Disease at Day 42 scan were in the low dose Cohorts.

The Oct 31 results were really very good overall. This slide tells me that the next data cut - whenever we get that - is likely to show even better results, because it will have the patients who came in the later, higher dose, cohorts.

Also worth noting - Slide 32: It tells us that the Complete Response patient on the PD1-vaxx trial is still going strong! Now "3 years +" !!! That's great news - especially for the lucky patient.

Cheers

Dave